Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

Dr. Reddy's to commercialise Tegoprazan in India and six emerging markets

HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales

Terran Biosciences announces licensing deal with Sanofi

Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics

Vipergen’s DNA based drug discovery partnership with Theseus Pharma

Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target

Alvotech settles with AbbVie to secure US rights to Humira biosimilar

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023

ITM receives investment of EUR 25 mn from Grand Pharma

Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China

Lilly and Entos collaborate for therapies in multiple neurologic indications

Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly

Novavax and SK bioscience expand manufacturing agreement

SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market

Biogen and TheraPanacea collaborate to advance digital health in neuroscience

Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology

Dr Reddy’s and Prestige BioPharma collaborate to commercialise trastuzumab biosimilar

The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia